As of Nov 19, 2026, 1 of 1 active firms rate CTSO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CTSO EPS & revenue forecast
EPS · NEXT QUARTER
$0.00
Range $0.00 – $0.00 · 1 analysts · -100% YoY
Next period, 1 analysts expect Cytosorbents Crp to earn $0.00 a share (range $0.00 – $0.00), versus $-1.60 a year earlier. Full-year consensus is $-4.40, growing to $0.00 the year after.
REVENUE · NEXT QUARTER
$10.8M
Range $10.8M – $10.8M · 1 analysts · +22% YoY
Revenue is expected to reach $10.8M (range $10.8M – $10.8M), +21.8% year-over-year. Full-year consensus is $38.9M, rising to $44.2M next year.
Top analysts covering Cytosorbents Crp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTSO.
#1
Sean Lee
HC Wainwright & Co. · Rank #344
Neutral
$0.75-86.0% to target
Overall win rate
40%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #562
Buy
$10.00+86.2% to target
Overall win rate
22%
+ Follow
#3
SL
Sean Lee CFA
H.C. Wainwright
Neutral
$15.00+179.3% to target
Coverage
—
+ Follow
CTSO stock forecast FAQ
What is CTSO's average 12-month price target?+
The 1 active firms with a live target average $10.00 for Cytosorbents Crp over the next 12 months, ranging from a $10.00 high to a $10.00 low, as of Nov 19, 2026.
Is CTSO stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover CTSO?+
1 active firms have a recognized rating on Cytosorbents Crp as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CTSO?+
Among analysts who currently cover CTSO, Sean Lee of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #344). Their current call is Neutral with a $0.75 target.
What is Cytosorbents Crp's projected EPS for next quarter?+
The consensus estimate is $0.00 per share (range $0.00 – $0.00) across 1 analysts. Full-year EPS is projected at $-4.40, rising to $0.00 the following year.
How much revenue is Cytosorbents Crp expected to report next quarter?+
Consensus revenue is $10.8M (range $10.8M – $10.8M). Full-year revenue is projected at $38.9M, growing to $44.2M next year.
Have analysts been upgrading or downgrading CTSO lately?+
As of Nov 19, 2026, 1 of 1 active firms rate CTSO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTSO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.